Mucosal immune response mediators

Mucosal immune response mediators are a diverse group of molecules, including cytokines, chemokines, and immunoglobulins, that coordinate immune activity at mucosal surfaces such as the gut and lungs (Source: NIH, StatPearls). These mediators, such as secretory IgA and interleukin-10, are essential for maintaining mucosal homeostasis and protecting against pathogens (Source: Nature Reviews Immunology). Adhesion molecules like MAdCAM-1 and the integrin alpha-4 beta-7 are also critical mediators, as they facilitate the tissue-specific homing of leukocytes to mucosal sites (Source: UniProt). Dysregulation of these mediators is a primary driver of chronic inflammatory conditions, most notably inflammatory bowel disease (IBD) and asthma (Source: PubMed). Therapeutic strategies often target specific mediators within this group; for instance, Vedolizumab inhibits the alpha-4 beta-7 integrin to treat ulcerative colitis and Crohn's disease (Source: FDA, PubChem). Other drugs, such as Infliximab and Ustekinumab, target pro-inflammatory cytokines like TNF-alpha and IL-12/23 to reduce mucosal inflammation (Source: Mayo Clinic). By modulating these mediators, clinicians can manage autoimmune responses while attempting to preserve the protective functions of the mucosal barrier.

Other names

Mucosal immune factorsMucosal inflammatory mediatorsMucosal immune system componentsMucosal defense mediators

Inhibition of specific mucosal homing receptors or neutralization of pro-inflammatory cytokines to reduce pathological inflammation at mucosal surfaces.